Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine.
Lau-Min KS, Marini J, Shah NK, Pucci D, Blauch AN, Cambareri C, Mooney B, Agarwal P, Johnston C, Schumacher RP, White K, Gabriel PE, Rosin R, Jacobs LA, Shulman LN. Lau-Min KS, et al. Among authors: cambareri c. JCO Oncol Pract. 2024 Apr;20(4):483-490. doi: 10.1200/OP.23.00365. Epub 2024 Jan 18. JCO Oncol Pract. 2024. PMID: 38237102
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing.
Varughese LA, Bhupathiraju M, Hoffecker G, Terek S, Harr M, Hakonarson H, Cambareri C, Marini J, Landgraf J, Chen J, Kanter G, Lau-Min KS, Massa RC, Damjanov N, Reddy NJ, Oyer RA, Teitelbaum UR, Tuteja S. Varughese LA, et al. Among authors: cambareri c. Front Oncol. 2022 Jul 5;12:859846. doi: 10.3389/fonc.2022.859846. eCollection 2022. Front Oncol. 2022. PMID: 35865463 Free PMC article.
DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese LA, Lau-Min KS, Cambareri C, Damjanov N, Massa R, Reddy N, Oyer R, Teitelbaum U, Tuteja S. Varughese LA, et al. Among authors: cambareri c. Pharmacotherapy. 2020 Nov;40(11):1108-1129. doi: 10.1002/phar.2463. Epub 2020 Oct 19. Pharmacotherapy. 2020. PMID: 32985005 Free PMC article. Review.
2020-2021 Drug Updates in Solid Tumors.
Cambareri C. Cambareri C. J Adv Pract Oncol. 2022 Apr;13(3):275-281. doi: 10.6004/jadpro.2022.13.3.19. Epub 2022 May 23. J Adv Pract Oncol. 2022. PMID: 35663163 Free PMC article.
Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America.
Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, Cheng RK, Kittleson MM, Upshaw JN, Palaskas N, Blaes A, Brown SA, Ky B, Lenihan D, Maurer MS, Fadol A, Skurka K, Cambareri C, Chauhan C, Barac A. Bloom MW, et al. Among authors: cambareri c. J Card Fail. 2024 Oct 15:S1071-9164(24)00363-4. doi: 10.1016/j.cardfail.2024.08.045. Online ahead of print. J Card Fail. 2024. PMID: 39419165 Review.
Cardio-Oncology and Heart Failure: AL Amyloidosis for the Heart Failure Clinician: a Supplement to the Scientific Statement from the Heart Failure Society of America.
Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, Cheng RK, Kittleson MM, Upshaw JN, Palaskas N, Blaes A, Brown SA, Ky B, Lenihan D, Maurer MS, Fadol A, Skurka K, Cambareri C, Barac A. Bloom MW, et al. Among authors: cambareri c. J Card Fail. 2024 Oct 15:S1071-9164(24)00364-6. doi: 10.1016/j.cardfail.2024.08.046. Online ahead of print. J Card Fail. 2024. PMID: 39414560 No abstract available.